Natixis Advisors, L.P. Repligen Corp Transaction History
Natixis Advisors, L.P.
- $51.3 Billion
- Q3 2024
A detailed history of Natixis Advisors, L.P. transactions in Repligen Corp stock. As of the latest transaction made, Natixis Advisors, L.P. holds 33,625 shares of RGEN stock, worth $5.32 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
33,625
Previous 21,894
53.58%
Holding current value
$5.32 Million
Previous $2.76 Million
81.3%
% of portfolio
0.01%
Previous 0.01%
Shares
13 transactions
Others Institutions Holding RGEN
# of Institutions
489Shares Held
54.3MCall Options Held
341KPut Options Held
235K-
Black Rock Inc. New York, NY7.57MShares$1.2 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$1.01 Billion0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.04MShares$798 Million0.01% of portfolio
-
State Street Corp Boston, MA1.62MShares$257 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.42MShares$225 Million1.34% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $8.78B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....